Pixium Vision raises €34.5 million in successful IPO
Pixium Vision, a company developing innovative Vision Restoration Systems (VRS) to allow patients who have lost their sight lead more independent lives, announced the successful completion of its Initial Public Offering (IPO) on Euronext’s regulated market in Paris (Euronext Paris) raising a total of €34.5 million. The Board of Directors of Pixium Vision SA met on June 17, 2014 and decided to fully exercise the extension clause. Pixium Vision will issue 4,166,666 new shares at a price of €8.28 per share. Upon listing, Pixium Vision will have a market capitalization of €100.4 million ($135.9 million) based on the offer price.
Bernard Gilly, Executive Chairman and founder of Pixium Vision, said: “The success of our IPO reflects investors’ confidence in Pixium Vision’s strategy. With our complementary technologies IRIS® and PRIMA, we are ideally positioned to become a world leader of the VRS market, and thereby enable people who have lost their sight to live more independently and play a greater role in society.”
Pixium Vision will use the proceeds raised from the IPO to support the clinical development and commercial launch of its IRIS® VRS in Europe and the United States, as well as the development of the PRIMA VRS to the point of its commercialization in Europe.
Other news from the department business & finance
